133 related articles for article (PubMed ID: 6099766)
1. Influence of the converting enzyme inhibitors Hoe 498, enalapril and captopril on vascular reactivity of isolated arterial preparations.
Schölkens BA; Xiang JZ; Tilly H
Clin Exp Hypertens A; 1984; 6(10-11):1807-13. PubMed ID: 6099766
[No Abstract] [Full Text] [Related]
2. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498 diacid). Comparison with captopril and enalaprilat.
Bünning P
Arzneimittelforschung; 1984; 34(10B):1406-10. PubMed ID: 6097266
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Becker RH; Schölkens BA; Metzger M; Schulze KJ
Arzneimittelforschung; 1984; 34(10B):1411-6. PubMed ID: 6097267
[TBL] [Abstract][Full Text] [Related]
4. [Comparisons of effects of Hoe-498 and enalapril in isolated guinea pig hearts and rat myocardium].
Xiang JZ; Schölkens BA; Linz W; Unger T; Ganten D; Lang RE
Zhongguo Yao Li Xue Bao; 1985 Jun; 6(2):96-9. PubMed ID: 3002124
[No Abstract] [Full Text] [Related]
5. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.
Unger T; Fleck T; Ganten D; Lang RE; Rettig F
Arzneimittelforschung; 1984; 34(10B):1426-30. PubMed ID: 6097269
[TBL] [Abstract][Full Text] [Related]
6. Unchanged pressor effect of norepinephrine in normal man following the oral administration of two angiotensin converting enzyme inhibitors, captopril and HOE 498.
Vierhapper H; Witte PU; Waldhäusl W
J Hypertens; 1986 Feb; 4(1):9-11. PubMed ID: 3007605
[TBL] [Abstract][Full Text] [Related]
7. Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1984; 6(5):872-80. PubMed ID: 6209494
[TBL] [Abstract][Full Text] [Related]
8. 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor.
Metzger H; Maier R; Sitter C; Stern HO
Arzneimittelforschung; 1984; 34(10B):1402-6. PubMed ID: 6097265
[TBL] [Abstract][Full Text] [Related]
9. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.
van Gilst WH; de Graeff PA; Wesseling H; de Langen CD
J Cardiovasc Pharmacol; 1986; 8(4):722-8. PubMed ID: 2427810
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of the dipeptidyl peptidase inhibitors captopril, ramipril, and enalapril on water intake and sodium appetite of Sprague-Dawley rats.
Rowland NE; Fregly MJ
Behav Neurosci; 1988 Dec; 102(6):953-60. PubMed ID: 2850816
[TBL] [Abstract][Full Text] [Related]
11. Effect of angiotensin-converting enzyme inhibitor Hoe-498 on noradrenaline-induced vasoconstriction in isolated perfused mesentery of rats.
Xiang JZ; Schölkens BA
Zhongguo Yao Li Xue Bao; 1984 Jun; 5(2):104-5. PubMed ID: 6087609
[No Abstract] [Full Text] [Related]
12. New potent inhibitors of angiotensin converting enzyme.
Attwood MR; Francis RJ; Hassall CH; Kröhn A; Lawton G; Natoff IL; Nixon JS; Redshaw S; Thomas WA
FEBS Lett; 1984 Jan; 165(2):201-6. PubMed ID: 6319181
[TBL] [Abstract][Full Text] [Related]
13. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Cushman DW; Wang FL; Fung WC; Grover GJ; Harvey CM; Scalese RJ; Mitch SL; DeForrest JM
Br J Clin Pharmacol; 1989; 28 Suppl 2(Suppl 2):115S-130S; discussion 130S-131S. PubMed ID: 2557876
[TBL] [Abstract][Full Text] [Related]
14. Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.
Unger T; Ganten D; Lang RE; Schölkens BA
J Cardiovasc Pharmacol; 1985; 7(1):36-41. PubMed ID: 2580148
[TBL] [Abstract][Full Text] [Related]
15. Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.
Mauersberger H; Witte PU
Lancet; 1985 Mar; 1(8427):517-8. PubMed ID: 2857878
[No Abstract] [Full Text] [Related]
16. Influence of captopril and enalapril on regional vascular alpha-adrenergic receptor reactivity in SHR.
Richer C; Doussau MP; Giudicelli JF
Hypertension; 1984; 6(5):666-74. PubMed ID: 6094343
[TBL] [Abstract][Full Text] [Related]
17. Effects of captopril and enalapril on regional vascular resistance and reactivity in spontaneously hypertensive rats.
Richer C; Doussau MP; Giudicelli JF
Hypertension; 1983; 5(3):312-20. PubMed ID: 6188693
[TBL] [Abstract][Full Text] [Related]
18. Comparison of angiotensin converting enzyme inhibitors captopril and MK421-diacid in guinea pig atria.
Nakashima A; Angus JA; Johnston CI
Eur J Pharmacol; 1982 Jul; 81(3):487-92. PubMed ID: 6288415
[TBL] [Abstract][Full Text] [Related]
19. The present molecules of converting enzyme inhibitors.
Brunner HR; Nussberger J; Waeber B
J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S2-11. PubMed ID: 2580170
[TBL] [Abstract][Full Text] [Related]
20. Effects of chronic converting enzyme inhibition on the vascular renin-angiotensin system.
Saito H; Nakamaru M; Rakugi H; Mikami H; Ogihara T; Inagami T
Clin Exp Pharmacol Physiol; 1990 Nov; 17(11):745-53. PubMed ID: 2150362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
